{"organizations": [], "uuid": "41973daa25c98ff89fe31a784caf1663028210b0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180222.html", "section_title": "Archive News &amp; Video for Thursday, 22 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-arbutus-settles-litigation-termina/brief-arbutus-settles-litigation-terminating-acuitas-rights-to-lnp-technology-idUSFWN1QC18A", "country": "US", "domain_rank": 408, "title": "BRIEF-Arbutus Settles Litigation Terminating Acuitas Rights To LNP Technology", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.993, "site_type": "news", "published": "2018-02-23T05:38:00.000+02:00", "replies_count": 0, "uuid": "41973daa25c98ff89fe31a784caf1663028210b0"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-arbutus-settles-litigation-termina/brief-arbutus-settles-litigation-terminating-acuitas-rights-to-lnp-technology-idUSFWN1QC18A", "ord_in_thread": 0, "title": "BRIEF-Arbutus Settles Litigation Terminating Acuitas Rights To LNP Technology", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "arbutus biopharma corp", "sentiment": "negative"}, {"name": "lnp", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "columbia", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 22 (Reuters) - Arbutus Biopharma Corp:\n* ARBUTUS SETTLES LITIGATION, TERMINATING ACUITAS’ RIGHTS TO LNP TECHNOLOGY\n* ARBUTUS BIOPHARMA CORP - ‍SETTLEMENT TERMINATES ACUITAS’ RIGHT TO USE OR SUBLICENSE OUR LNP TECHNOLOGY GOING FORWARD​\n* ARBUTUS BIOPHARMA - ‍SETTLEMENT STIPULATES THAT 4 NON-EXCLUSIVE VIRAL VACCINE SUBLICENSES PREVIOUSLY GRANTED TO MODERNA ARE ONLY SUBLICENSES TO SURVIVE​\n* ARBUTUS BIOPHARMA - LITIGATION INITIATED BY ACUITAS THERAPEUTICS ON OCT. 25, 2016 IN SUPREME COURT OF BRITISH COLUMBIA HAS BEEN SETTLED BEFORE TRIAL​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-23T05:38:00.000+02:00", "crawled": "2018-02-23T16:14:02.013+02:00", "highlightTitle": ""}